Color keeps GSK generic off the market

Sandoz's AirFluSal Forspiro
Sandoz's AirFluSal Forspiro

A purple casing is keeping Sandoz from being able to market its generic of GlaxoSmithKline's COPD drug Advair in Germany.

The Wall Street Journal reports that GSK filed a preliminary injunction against the Novartis generics division because the Sandoz inhaler for its AirFluSal Forspiro inhaler is purple, just like the inhaler for GSK's Advair (known as Seretide and Viani), claiming unfair competition.

"Glaxo says it believes customers recognize the color purple as indicating its own product and Forspiro's appearance could lead to confusion among patients, pharmacists and healthcare providers,” reports the WSJ.

You must be a registered member of MMM to post a comment.
close

Next Article in Pharmaceutical

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.